Monday, February 9, 2009

For Antidepressants, Maybe Three Targets Will Be Better than Two

AstraZeneca is the latest drug maker to study a new class of antidepressants called triple reuptake inhibitors, or TRIs.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)